PT93178A - Agente proteico anticanceroso - Google Patents

Agente proteico anticanceroso

Info

Publication number
PT93178A
PT93178A PT93178A PT9317890A PT93178A PT 93178 A PT93178 A PT 93178A PT 93178 A PT93178 A PT 93178A PT 9317890 A PT9317890 A PT 9317890A PT 93178 A PT93178 A PT 93178A
Authority
PT
Portugal
Prior art keywords
modified
recognition protein
anticanceroso
cell recognition
toxin
Prior art date
Application number
PT93178A
Other languages
English (en)
Other versions
PT93178B (pt
Inventor
Deborah D Jones
Allen Oliff
Gwynneth M Edwards
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PT93178A publication Critical patent/PT93178A/pt
Publication of PT93178B publication Critical patent/PT93178B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT93178A 1989-02-17 1990-02-16 Agente proteico anticanceroso PT93178B (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31254089A 1989-02-17 1989-02-17
US38909289A 1989-08-03 1989-08-03
US44918789A 1989-12-21 1989-12-21

Publications (2)

Publication Number Publication Date
PT93178A true PT93178A (pt) 1990-08-31
PT93178B PT93178B (pt) 1996-04-30

Family

ID=27405603

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93178A PT93178B (pt) 1989-02-17 1990-02-16 Agente proteico anticanceroso

Country Status (18)

Country Link
EP (1) EP0383599B1 (pt)
JP (2) JPH07106159B2 (pt)
KR (1) KR0169729B1 (pt)
AT (1) ATE133993T1 (pt)
AU (1) AU617039B2 (pt)
CA (1) CA2010256C (pt)
CY (1) CY1987A (pt)
DE (1) DE69025211T2 (pt)
DK (1) DK0383599T3 (pt)
ES (1) ES2085329T3 (pt)
FI (1) FI102383B (pt)
GR (1) GR3019836T3 (pt)
HK (1) HK15597A (pt)
IE (1) IE71934B1 (pt)
IL (1) IL93425A (pt)
NO (1) NO300595B1 (pt)
NZ (1) NZ232564A (pt)
PT (1) PT93178B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
JPH0829101B2 (ja) * 1989-04-21 1996-03-27 アメリカ合衆国 組換え抗体―毒素融合タンパク質
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
AUPM959894A0 (en) * 1994-11-22 1994-12-15 Crc For Biopharmaceutical Research Pty Ltd Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4
CA2276091A1 (en) * 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs
CA2289117A1 (en) * 1997-05-12 1998-11-19 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method and construct for inhibition of cell migration
GB0008802D0 (en) * 2000-04-10 2000-05-31 Univ London Molecule
WO2006001023A2 (en) * 2004-06-28 2006-01-05 Yeda Research And Development Co. Ltd Chimeric proteins and uses thereof
WO2015076121A1 (ja) 2013-11-20 2015-05-28 株式会社村田製作所 多層配線基板およびこれを備えるプローブカード
US20180250360A1 (en) * 2015-10-05 2018-09-06 National Institute Of Advanced Industrial Science And Technology Method for detecting cancer cells, reagent for introducing substance into cancer cells, and composition for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
JPH0829101B2 (ja) * 1989-04-21 1996-03-27 アメリカ合衆国 組換え抗体―毒素融合タンパク質

Also Published As

Publication number Publication date
ATE133993T1 (de) 1996-02-15
IE900587L (en) 1990-08-17
JPH07106159B2 (ja) 1995-11-15
IE71934B1 (en) 1997-03-12
NO900758D0 (no) 1990-02-16
AU617039B2 (en) 1991-11-14
FI102383B1 (fi) 1998-11-30
FI102383B (fi) 1998-11-30
CY1987A (en) 1997-09-05
JPH07278200A (ja) 1995-10-24
JPH02276590A (ja) 1990-11-13
EP0383599B1 (en) 1996-02-07
JP2510846B2 (ja) 1996-06-26
PT93178B (pt) 1996-04-30
ES2085329T3 (es) 1996-06-01
KR900012626A (ko) 1990-09-01
IL93425A (en) 1999-08-17
IL93425A0 (en) 1990-11-29
HK15597A (en) 1997-02-14
GR3019836T3 (en) 1996-08-31
NZ232564A (en) 1992-08-26
DK0383599T3 (da) 1996-08-05
NO300595B1 (no) 1997-06-23
CA2010256C (en) 2000-07-25
CA2010256A1 (en) 1990-08-17
DE69025211T2 (de) 1996-09-19
AU4994690A (en) 1990-08-23
FI900783A0 (fi) 1990-02-16
NO900758L (no) 1990-08-20
KR0169729B1 (ko) 1999-01-15
DE69025211D1 (de) 1996-03-21
EP0383599A3 (en) 1991-03-27
EP0383599A2 (en) 1990-08-22

Similar Documents

Publication Publication Date Title
DE3686654D1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
DE3650751D1 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
DE69632658D1 (de) Expression in der selben Zelle von Polypeptide vom schweinen reproduktiven und respiratorischen Syndrom
PT94633A (pt) Metodo para a desnaturacao oxidante de analitos de proteina
PT93178A (pt) Agente proteico anticanceroso
SE8007074L (sv) Glukagonfragment jemte dess anvendning
NO881904L (no) Fremgangsmaate til selektiv immunologisk bestemmelse av intakt prokollagen peptid (type iii) og prokollagen (type iii) i kroppsvaesker, og middel til dets gjennomfoering.
ES2109225T3 (es) Anticuerpos, su produccion y uso.
DK515889D0 (da) Hidtil ukendt fremgangsmaade
KR910003092A (ko) 항체 정제 방법에 사용하기 위한 hcg펩티드
EP0293827A3 (en) Assay for leishmaniasis
ATE103973T1 (de) Gamma-atriales, natriuretisches polypeptid erkennende monoklonale antikoerper, solche antikoerper produzierende hybridome und deren herstellung und verwendung.

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19960122

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19970731

NF3A Restitutio in integrum

Effective date: 19980213

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20040722